A powerful whole
organism model for accelerating ageing research
Strong phenotypic models for testing therapeutics and products in a naturally ageing organism
Neurodegenerative diseases are chronic and debilitating conditions linked with age, with few therapeutic interventions. The incidence of Alzheimer's, Parkinson’s and related diseases are set to double every 20 years as the population ages globally1.
C. elegans provides effective models of neurodegenerative disease through overexpression of human proteins implicated in their pathophysiology. These loss of function models age in weeks, with characteristic neurodegenerative phenotypes that can be scored rapidly and used to test diverse interventions with our WormGazerTM technology.
We provide you with a strong phenotypic model system for neurodegenerative diseases, including muscular changes that result in variable paralysis and neurological changes that affect mobility and cognitve behaviours.
This is combined with the ability to continuously track and quantify these complex changes, in real time, using our automated WormGazerTM technology.
Contact us for more information and data examples from our in-house C. elegans models of Huntington’s Disease, Alzheimer's Disease, Parkinson’s Disease. See our Transgenics page to discover how we can make a custom model designed for your specific needs.
Ageing is a major risk factor for neurodegeneration and associated diseases. As such, we also offer assays for neuronal functional decline using naturally ageing, wild type populations. These models are free from the overexpression of proteins or pathway induction.
Neurotransmission in C. elegans uses several identical receptors and signalling pathways to mammals, allowing its successful use to model neuronal function2. These include acetylcholine (ACh), g-aminobutyric acid (GABA), dopamine, serotonin and glutamate. Excitatory neurotransmission at the neuromuscular junction is elicited through ACh and inhibited by GABA.
In this video, we demonstrate the use of our unique WormGazerTM technology to measure mobility decline in a C. elegans strain modified to express the human amyloid peptide (Aβ 1-42) as a model for Alzheimer’s disease vs a wild-type control model
Download our poster: Developing a System to Quantify Efficacy of Neurodegeneration Therapeutics Using Automated Monitoring of C. elegans
SERVICES
Contract lab services for
your research area
Sign up to our newsletter today, to get access to the latest company and industry news